Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Concomitant Ruxolitinib Induction and Maintenance With Cytarabine Based Chemotherapy in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm

NCT03558607 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT03558607
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03558607 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Concomitant Ruxolitinib Induction and Maintenance With Cytarabine Based Chemotherapy in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm
Lead sponsor
Seoul National University Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
May 17, 2018
Completion date
August 31, 2024
Enrollment
17 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

secondary acute myelogenous leukemia evolving from myeloproliferative disorder